Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: Potential implications in tumor progression and therapeutics

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1598-1610

  Li, Chien Feng ^a,b,c,e   Wang, Ju Ming ^d   Kang, Hong Yo ^f   Huang, Chiung Kuei ^f   Wang, Jun Wen ^g   Fang, Fu Min ^g   Wang, Yu Hui ^d   Wu, Wen Ren ^e   Li, Shau Hsuan ^g   Yu, Shih Chen ^g   Lee, Jen Chieh ^h   Lan, Jui ^g   Shiue, Yow Ling ^e   Wu, Li Ching ^a   Huang, Hsuan Ying ^g  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f Graduate Institute of Clinical Medical Science   (Taiwan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA; MESSENGER RNA; S PHASE KINASE ASSOCIATED PROTEIN 2;

ACTN1 GENE; ADULT; AMACR GENE; AMPLICON; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME 5P; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; EMBRYO; ENAH GENE; ENZYME ACTIVATION; FEMALE; FIBROBLAST; FIBROMYXOSARCOMA; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF1 GENE; IN VITRO STUDY; IN VIVO STUDY; ITGB2 GENE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SKP2 GENE; SOFT TISSUE SARCOMA; TRIO GENE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BORONIC ACIDS; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FIBROSARCOMA; GENE AMPLIFICATION; GENE DOSAGE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PYRAZINES; RACEMASES AND EPIMERASES; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863253129     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3077     Document Type: Article

References (42)

1. Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 2004;35:612-21. (Pubitemid 38656947)
2. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 1996;20:391-405. (Pubitemid 26113344)
3. Lin CN, Chou SC, Li CF, Tsai KB, Chen WC, Hsiung CY, et al. Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol 2006;93:294-303.
4. Oda Y, Takahira T, Kawaguchi K, Yamamoto H, Tamiya S, Matsuda S, et al. Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications. Hum Pathol 2003;34:1035-42. (Pubitemid 37315256)
5. Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 2011;18:720-5.
6. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42:715-21.
7. Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 2006;19:407-16. (Pubitemid 43276995)
8. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263-4. (Pubitemid 33096449)
9. Huang HY, Kang HY, Li CF, Eng HL, Chou SC, Lin CN, et al. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res 2006;12:487-98.
10. Kawashima H, Ogose A, Gu W, Nishio J, Kudo N, Kondo N, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet 2005;161:28-35. (Pubitemid 41096048)
11. Krause AK, Hinrichs SH, Orndal C, DeBoer J, Neff JR, Bridge JA. Characterization of a human myxoid malignant fibrous histiocytoma cell line, OH931. Cancer Genet Cytogenet 1997;94:138-43. (Pubitemid 27169348)
12. Huang HY, Li CF, Fang FM, Tsai JW, Li SH, Lee YT, et al. Prognostic implication of ezrin overexpression in myxofibrosarcomas. Ann Surg Oncol 2010;17:3212-9.
13. Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, et al. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol 2010;23:1379-92.
14. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001;25:409-18. (Pubitemid 34164013)
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8. (Pubitemid 34164012)
16. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008;112:1415-24. (Pubitemid 351441154)
17. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, et al. Bortezomib (Velcade) induces p27Kip1 expression through Sphase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008;68:3379-88.
18. Uddin S,Ahmed M, Hussain AR, Jehan Z, Al-Dayel F,Munkarah A, et al. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Lab Invest 2009;89:1115-27.
19. Garnis C, Davies JJ, Buys TP, Tsao MS, MacAulay C, Lam S, et al. Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene 2005;24:4806-12. (Pubitemid 41076298)
20. Scotto L, Narayan G, Nandula SV, Subramaniyam S, Kaufmann AM, Wright JD, et al. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer 2008;7:58.
21. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010;10:59-64.
22. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41-7. (Pubitemid 36269179)
23. Pagano M. Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell 2004;14:414-6. (Pubitemid 38648792)
24. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-26. (Pubitemid 32424119)
25. Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin 2006;56:282-91. (Pubitemid 44527490)
26. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, et al. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol 2010;12:457-67.
27. Wang XC,WuYP, Ye B, Lin DC, Feng YB, Zhang ZQ, et al. Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma. Mol Cancer Res 2009;7:12-22.
28. Hung WC, Tseng WL, Shiea J, Chang HC. Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 2010;288:156-61.
29. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev 2010;29:223-37.
30. Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 2006;108:1441-50. (Pubitemid 44316107)
31. Sampath R, Gallagher PJ, Pavalko FM. Cytoskeletal interactions with the leukocyte integrin beta2 cytoplasmic tail. Activation-dependent regulation of associations with talin and alpha-actinin. J Biol Chem 1998;273:33588-94.
32. Wang HS, Hung Y, SuCH, Peng ST, Guo YJ, Lai MC, et al. CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (alpha L beta2) and VLA-4 (alpha4beta1). Exp Cell Res 2005;304:116-26.
33. Craig DH, Haimovich B, Basson MD. Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction. Am J Physiol Cell Physiol 2007;293:C1862-74. (Pubitemid 350255082)
34. Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2003;2:630-5.
35. Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008;19:1293-8. (Pubitemid 351911960)
36. Cironi L, Riggi N, Provero P, Wolf N, Suva ML, Suva D, et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008;3:e2634.
37. Di Modugno F, Mottolese M, DeMonte L, Trono P, Balsamo M, Conidi A, et al. The cooperation between hMena overexpression and HER2 signalling in breast cancer. PLoS One 2010;5:e15852.
38. Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, Giampieri S, et al.AMena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 2008;15:813-28.
39. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007;13:5942-51. (Pubitemid 47583922)
40. Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A, et al. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol 2010;66:455-66.
41. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 2009;15:553-60.
42. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010;16:4094-104.